[
    {
        "EligibilityCriteria": "Inclusion Criteria:\n\n1. Age \u2265 18 years (or legal adult age within country, whichever is older) at the time that the Informed Consent Form (ICF) is signed\n2. Histologically or cytologically confirmed cancer of one of the following types, refractory to or relapsed after at least 1 prior standard therapeutic regimen in the advanced/metastatic setting, as specified below. If no standard of care therapies exist for the participant, or the participant cannot tolerate or refuses standard of care anticancer therapy, the participant may be allowed to participate on the study after discussion between the investigator and Amgen medical monitor. Participants who have not received all approved or standard treatments for their cancer must be informed that these alternatives to receiving bemarituzumab are available prior to consenting to participate in the trial.\n\n   * head and neck squamous cell carcinoma: \u2265 1 line of therapy\n   * triple-negative breast cancer: \u2265 2 lines of therapy\n   * Intrahepatic cholangiocarcinoma \u2265 1 line of therapy\n   * lung adenocarcinoma: at least platinum-based chemotherapy, checkpoint inhibitor, and targeted therapy\n   * platinum resistant ovarian epithelial cell carcinoma, including fallopian tube cancers and primary peritoneal cancers, defined as progression during or within 6 months of a platinum containing regimen: \u2265 1 line of therapy\n   * endometrial adenocarcinoma: \u2265 1 line of therapy\n   * cervical carcinoma: \u2265 1 line of therapy\n   * other solid tumors: \u2265 1 line of therapy\n3. Disease that is unresectable, locally advanced, or metastatic (not amenable to curative therapy)\n4. Tumor overexpresses FGFR2b as determined by centrally performed immunohistochemistry (IHC) testing\n5. Measurable disease per Response Evaluation Criteria in Solid Tumors Version 1.1\n6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n7. Adequate organ function as determined per protocol.\n\nExclusion Criteria:\n\n1. Untreated or symptomatic central nervous system (CNS) metastases or leptomeningeal disease.\n2. Other solid tumor cohort excludes primary tumors of the CNS, squamous non-small cell lung cancer, gastric adenocarcinoma, and gastroesophageal junction adenocarcinoma\n3. Impaired cardiac function or clinically significant cardiac disease including: unstable angina within 6 months prior to first dose of study treatment, acute myocardial infarction \u2265 6 months prior to first dose of study treatment, New York Heart Association (NYHA) class II-IV congestive heart failure, uncontrolled hypertension (defined as an average systolic blood pressure \u2265 160 mmHg or diastolic \u2265 100 mmHg despite optimal treatment, uncontrolled cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers or digoxin, active coronary artery disease or corrected QT interval QTc \u2265 470\n4. History of systemic disease or ophthalmologic disorders requiring chronic use of ophthalmic steroids\n5. Evidence of any ongoing ophthalmologic abnormalities or symptoms that are acute (within 4 weeks) or actively progressing\n6. Unwillingness to avoid use of contact lenses during study treatment and for at least 100 days after the end of treatment\n7. Recent (within 6 months) corneal surgery or ophthalmic laser treatment or recent (within 6 months) history of, or evidence of, corneal defects, corneal ulcerations, keratitis, or keratoconus, or other known abnormalities of the cornea that may pose an increased risk of developing a corneal ulcer prior/concomitant therapy\n8. Prior treatment with any investigational selective inhibitor of the fibroblast growth factor (FGF)/FGF receptor pathway (unless approved standard of care for tumor indication).",
        "InclusionCriteria": "1. Age \u2265 18 years (or legal adult age within country, whichever is older) at the time that the Informed Consent Form (ICF) is signed\n2. Histologically or cytologically confirmed cancer of one of the following types, refractory to or relapsed after at least 1 prior standard therapeutic regimen in the advanced/metastatic setting, as specified below. If no standard of care therapies exist for the participant, or the participant cannot tolerate or refuses standard of care anticancer therapy, the participant may be allowed to participate on the study after discussion between the investigator and Amgen medical monitor. Participants who have not received all approved or standard treatments for their cancer must be informed that these alternatives to receiving bemarituzumab are available prior to consenting to participate in the trial.\n\n   * head and neck squamous cell carcinoma: \u2265 1 line of therapy\n   * triple-negative breast cancer: \u2265 2 lines of therapy\n   * Intrahepatic cholangiocarcinoma \u2265 1 line of therapy\n   * lung adenocarcinoma: at least platinum-based chemotherapy, checkpoint inhibitor, and targeted therapy\n   * platinum resistant ovarian epithelial cell carcinoma, including fallopian tube cancers and primary peritoneal cancers, defined as progression during or within 6 months of a platinum containing regimen: \u2265 1 line of therapy\n   * endometrial adenocarcinoma: \u2265 1 line of therapy\n   * cervical carcinoma: \u2265 1 line of therapy\n   * other solid tumors: \u2265 1 line of therapy\n3. Disease that is unresectable, locally advanced, or metastatic (not amenable to curative therapy)\n4. Tumor overexpresses FGFR2b as determined by centrally performed immunohistochemistry (IHC) testing\n5. Measurable disease per Response Evaluation Criteria in Solid Tumors Version 1.1\n6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n7. Adequate organ function as determined per protocol.",
        "ExclusionCriteria": "1. Untreated or symptomatic central nervous system (CNS) metastases or leptomeningeal disease.\n2. Other solid tumor cohort excludes primary tumors of the CNS, squamous non-small cell lung cancer, gastric adenocarcinoma, and gastroesophageal junction adenocarcinoma\n3. Impaired cardiac function or clinically significant cardiac disease including: unstable angina within 6 months prior to first dose of study treatment, acute myocardial infarction \u2265 6 months prior to first dose of study treatment, New York Heart Association (NYHA) class II-IV congestive heart failure, uncontrolled hypertension (defined as an average systolic blood pressure \u2265 160 mmHg or diastolic \u2265 100 mmHg despite optimal treatment, uncontrolled cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers or digoxin, active coronary artery disease or corrected QT interval QTc \u2265 470\n4. History of systemic disease or ophthalmologic disorders requiring chronic use of ophthalmic steroids\n5. Evidence of any ongoing ophthalmologic abnormalities or symptoms that are acute (within 4 weeks) or actively progressing\n6. Unwillingness to avoid use of contact lenses during study treatment and for at least 100 days after the end of treatment\n7. Recent (within 6 months) corneal surgery or ophthalmic laser treatment or recent (within 6 months) history of, or evidence of, corneal defects, corneal ulcerations, keratitis, or keratoconus, or other known abnormalities of the cornea that may pose an increased risk of developing a corneal ulcer prior/concomitant therapy\n8. Prior treatment with any investigational selective inhibitor of the fibroblast growth factor (FGF)/FGF receptor pathway (unless approved standard of care for tumor indication).",
        "HealthyVolunteers": false,
        "Gender": "ALL",
        "MinimumAge": "18 Years",
        "NCTId": "NCT05325866",
        "startDate": "",
        "completionDate": "",
        "durationDays": null,
        "daysUntilEnd": null
    },
    {
        "EligibilityCriteria": "Inclusion Criteria:\n\n* For Dose Escalation only: Participants with an advanced solid tumor who are considered refractory to or intolerant of all existing therapy(ies) known to provide a clinical benefit for their condition. Additionally, participants who have been offered standard therapies and refused, or who are considered ineligible for standard therapies, may be eligible for this study on a case-by-case basis, after discussion with and agreement from the sponsor. Participants with pancreatic adenocarcinoma, urothelial cancer (UC), hepatocellular carcinoma (HCC), or head and neck squamous cell carcinoma (HNSCC) who are being considered for the dose escalation cohorts must also meet the histology specific eligibility criteria described below for dose expansion.\n* For Dose Expansion only participants must meet criteria specific to the type of cancer:\n\n  * Pancreatic adenocarcinoma and have disease progression during or after 1 systemic therapy (gemcitabine monotherapy or in combination with other agents, FOLFIRINOX \\[or another regimen including both 5-fluorouracil and oxaliplatin\\], capecitabine monotherapy or in combination with other agents) administered in the adjuvant, locally advanced, or metastatic setting. If the therapy was used in an adjuvant setting, disease progression must have occurred within 6 months of completing adjuvant therapy.\n  * UC of the bladder and urinary tract and must have progressed following treatment with:\n  * Cohort 4: A platinum-based regimen (administered in any line of therapy) and a programmed death 1/programmed death ligand 1 (PD1/PDL1) antagonist administered in the recurrent or metastatic setting (progression following a PD1/PDL1 antagonist is defined as unequivocal progression on or within 3 months of the last dose of anti-PD1 or anti-PDL1 therapy).\n  * Cohort 11: One or more prior line of therapy in the locally advanced or metastatic setting. Participant must have experienced radiographic progression or relapse during or after a CPI (anti-PD1 or anti-PD-L1) for locally advanced or metastatic disease.\n  * HCC and must have disease progression during or after 1 prior line of systemic therapy.\n  * HNSCC (arising from the oral cavity, oropharynx, hypopharynx, or larynx) and must have progressed following treatment with platinum-based regimen (administered in any line of therapy) and a PD1/PDL1 antagonist administered in the recurrent or metastatic setting (progression following a PD1/PDL1 antagonist is defined as unequivocal progression on or within 3 months of the last dose of anti-PD1 or anti-PDL1 therapy).\n  * Microsatellite stable colorectal cancer (MSS-CRC) \\[unselected\\] participants with microsatellite stable or mismatch repair proficient colorectal adenocarcinoma (as determined by polymerase chain reaction (PCR)/Next-Generation sequencing (NGS) or immunohistochemistry (IHC), respectively) who have received 1-2 prior chemotherapy regimens.\n  * Non-small cell lung cancer (NSCLC) relapsed/refractory (R/R): Participants with histologically or cytologically confirmed advanced or metastatic NSCLC who have received 1 prior line of chemotherapy and 1 prior anti-PD-(L)1 antibody, administered either concurrently or sequentially in the metastatic setting.\n  * MSS-CRC (CMS4 enriched): Participants with microsatellite stable or mismatch repair proficient colorectal adenocarcinoma who have received prior fluorouracil-based combination chemotherapy regimens including oxaliplatin and irinotecan (with or without VEGF and/or EGFR targeted agents) and with a CMS4 subtype as determined by NGS of tumor biopsies. Archival tissue must be submitted for assessment of CMS4 subtype status during prescreening. Participants must have progressed on or refused available standard of care therapies. Additionally, participant who are considered not appropriate or ineligible for available standard of care therapies per investigator assessment will be eligible for this study.\n  * Ovarian granulosa (OG) cell tumor: Participants with histologically confirmed advanced nonresectable or metastatic adult granulosa cell tumor of the ovary that is not amenable to curative intent surgery or radiation. Additionally, there is documentation of radiological evidence of relapse after at least 1 line of systemic chemotherapy.\n* Participant has an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1.\n* Participant has adequate bone marrow, renal, hepatic, and coagulation function.\n* Must have a viral status consistent with the requirements described in the protocol specific to type of cancer and stage of study (Dose Escalation or Dose Expansion).\n\nExclusion Criteria:\n\n* For Dose Expansion only:\n\n  * Participants with HCC, pancreatic adenocarcinoma, or MSS-CRC having prior exposure to a prior PD-1/PD-L1 antagonist in any line of therapy.\n  * Participants (except for participants with urothelial cancer or HNSCC) who have had prior exposure to immunotherapies as listed in the protocol.\n* Has received anticancer therapy including chemotherapy, immunotherapy, radiation therapy, biologic, herbal therapy, or any investigational therapy within a period of 5 half-lives or 28 days (whichever is shorter), prior to the first dose of the study drug.\n* Participant has unresolved AEs \\> Grade 1 from prior anticancer therapy except for alopecia.\n* Has a history of primary immunodeficiency, bone marrow transplantation, solid organ transplantation, or previous clinical diagnosis of tuberculosis.\n* Has a known uncontrolled metastases to the central nervous system (with certain exceptions).\n* Current or prior use of immunosuppressive medication within 14 days prior to the first dose of the study drug.\n* Has clinically significant uncontrolled condition(s).\n* History of inflammatory bowel disease, interstitial lung disease or pneumonitis, myocarditis, Stevens-Johnson syndrome, toxic epidermal necrolysis or drug reaction with eosinophilia and systemic symptoms (DRESS).\n* Live vaccine administration \\<= 28 days prior to the first dose of study drug.",
        "InclusionCriteria": "* For Dose Escalation only: Participants with an advanced solid tumor who are considered refractory to or intolerant of all existing therapy(ies) known to provide a clinical benefit for their condition. Additionally, participants who have been offered standard therapies and refused, or who are considered ineligible for standard therapies, may be eligible for this study on a case-by-case basis, after discussion with and agreement from the sponsor. Participants with pancreatic adenocarcinoma, urothelial cancer (UC), hepatocellular carcinoma (HCC), or head and neck squamous cell carcinoma (HNSCC) who are being considered for the dose escalation cohorts must also meet the histology specific eligibility criteria described below for dose expansion.\n* For Dose Expansion only participants must meet criteria specific to the type of cancer:\n\n  * Pancreatic adenocarcinoma and have disease progression during or after 1 systemic therapy (gemcitabine monotherapy or in combination with other agents, FOLFIRINOX \\[or another regimen including both 5-fluorouracil and oxaliplatin\\], capecitabine monotherapy or in combination with other agents) administered in the adjuvant, locally advanced, or metastatic setting. If the therapy was used in an adjuvant setting, disease progression must have occurred within 6 months of completing adjuvant therapy.\n  * UC of the bladder and urinary tract and must have progressed following treatment with:\n  * Cohort 4: A platinum-based regimen (administered in any line of therapy) and a programmed death 1/programmed death ligand 1 (PD1/PDL1) antagonist administered in the recurrent or metastatic setting (progression following a PD1/PDL1 antagonist is defined as unequivocal progression on or within 3 months of the last dose of anti-PD1 or anti-PDL1 therapy).\n  * Cohort 11: One or more prior line of therapy in the locally advanced or metastatic setting. Participant must have experienced radiographic progression or relapse during or after a CPI (anti-PD1 or anti-PD-L1) for locally advanced or metastatic disease.\n  * HCC and must have disease progression during or after 1 prior line of systemic therapy.\n  * HNSCC (arising from the oral cavity, oropharynx, hypopharynx, or larynx) and must have progressed following treatment with platinum-based regimen (administered in any line of therapy) and a PD1/PDL1 antagonist administered in the recurrent or metastatic setting (progression following a PD1/PDL1 antagonist is defined as unequivocal progression on or within 3 months of the last dose of anti-PD1 or anti-PDL1 therapy).\n  * Microsatellite stable colorectal cancer (MSS-CRC) \\[unselected\\] participants with microsatellite stable or mismatch repair proficient colorectal adenocarcinoma (as determined by polymerase chain reaction (PCR)/Next-Generation sequencing (NGS) or immunohistochemistry (IHC), respectively) who have received 1-2 prior chemotherapy regimens.\n  * Non-small cell lung cancer (NSCLC) relapsed/refractory (R/R): Participants with histologically or cytologically confirmed advanced or metastatic NSCLC who have received 1 prior line of chemotherapy and 1 prior anti-PD-(L)1 antibody, administered either concurrently or sequentially in the metastatic setting.\n  * MSS-CRC (CMS4 enriched): Participants with microsatellite stable or mismatch repair proficient colorectal adenocarcinoma who have received prior fluorouracil-based combination chemotherapy regimens including oxaliplatin and irinotecan (with or without VEGF and/or EGFR targeted agents) and with a CMS4 subtype as determined by NGS of tumor biopsies. Archival tissue must be submitted for assessment of CMS4 subtype status during prescreening. Participants must have progressed on or refused available standard of care therapies. Additionally, participant who are considered not appropriate or ineligible for available standard of care therapies per investigator assessment will be eligible for this study.\n  * Ovarian granulosa (OG) cell tumor: Participants with histologically confirmed advanced nonresectable or metastatic adult granulosa cell tumor of the ovary that is not amenable to curative intent surgery or radiation. Additionally, there is documentation of radiological evidence of relapse after at least 1 line of systemic chemotherapy.\n* Participant has an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1.\n* Participant has adequate bone marrow, renal, hepatic, and coagulation function.\n* Must have a viral status consistent with the requirements described in the protocol specific to type of cancer and stage of study (Dose Escalation or Dose Expansion).",
        "ExclusionCriteria": "* For Dose Expansion only:\n\n  * Participants with HCC, pancreatic adenocarcinoma, or MSS-CRC having prior exposure to a prior PD-1/PD-L1 antagonist in any line of therapy.\n  * Participants (except for participants with urothelial cancer or HNSCC) who have had prior exposure to immunotherapies as listed in the protocol.\n* Has received anticancer therapy including chemotherapy, immunotherapy, radiation therapy, biologic, herbal therapy, or any investigational therapy within a period of 5 half-lives or 28 days (whichever is shorter), prior to the first dose of the study drug.\n* Participant has unresolved AEs \\> Grade 1 from prior anticancer therapy except for alopecia.\n* Has a history of primary immunodeficiency, bone marrow transplantation, solid organ transplantation, or previous clinical diagnosis of tuberculosis.\n* Has a known uncontrolled metastases to the central nervous system (with certain exceptions).\n* Current or prior use of immunosuppressive medication within 14 days prior to the first dose of the study drug.\n* Has clinically significant uncontrolled condition(s).\n* History of inflammatory bowel disease, interstitial lung disease or pneumonitis, myocarditis, Stevens-Johnson syndrome, toxic epidermal necrolysis or drug reaction with eosinophilia and systemic symptoms (DRESS).\n* Live vaccine administration \\<= 28 days prior to the first dose of study drug.",
        "HealthyVolunteers": false,
        "Gender": "ALL",
        "MinimumAge": "18 Years",
        "NCTId": "NCT03821935",
        "startDate": "",
        "completionDate": "",
        "durationDays": null,
        "daysUntilEnd": null
    },
    {
        "EligibilityCriteria": "Inclusion Criteria:\n\n1. \u2265 18 years old at the time of informed consent\n2. Ability to provide written informed consent and HIPAA authorization\n3. Locally recurrent (not amenable to local therapy with curative intent) or metastatic breast cancer that is triple negative or ER-low (ER and PR \u2264 9% weak staining)\n4. No prior chemotherapy for metastatic disease\n\n   a. Prior (neo)adjuvant therapy must have been completed at least 12 months from diagnosis of unresectable locally recurrent or metastatic disease.\n5. Measurable disease based on RECIST 1.1 criteria.\n6. Disease amenable to and consent for study-specific biopsy\n\n   a. NOTE: If no disease amenable to biopsy is present at the time of second biopsy, subjects may continue participation in the study and further study specific biopsies will not be required.\n7. ECOG PS 0 or 1\n8. Patients with treated, asymptomatic CNS disease may participate if the patient is \\> 4 weeks from completion of CNS therapy (radiation and/or surgery), is clinically stable at the time of study entry, and is receiving a stable or decreasing dose of corticosteroid therapy. Brain MRI or head CT is required at screening for patients with known brain metastases.\n9. Adequate organ function as indicated by:\n\n   1. Total bilirubin \\< ULN (except in patients with documented Gilbert's disease, who must have a total bilirubin \\< 3.0 mg/dL)\n   2. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \\< 5.0 x ULN\n   3. Creatinine clearance of \\> 50 mL/min using the Cockcroft-Gault formula\n   4. Absolute neutrophil count (ANC) \\> 1.5 K/mm3\n   5. Platelets \\> 100 K/ mm3\n   6. Hgb \\> 9.0 g/dL\n10. Women of childbearing potential must have a negative pregnancy test within 14 days of protocol registration. Women are considered to have childbearing potential (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) unless they meet one of the following criteria:\n\n    1. Has undergone a hysterectomy or bilateral oophorectomy; or\n    2. Has been naturally amenorrheic for at least 24 consecutive months.\n11. Women of childbearing potential and men must agree to use effective contraception throughout the study and for 6 months after the last study treatment.\n\nNote: Acceptable methods of birth control include abstinence, partner with previous vasectomy, placement of an intrauterine device (IUD), condom with spermicidal foam/gel/film/cream/suppository, diaphragm or cervical vault cap, or hormonal birth control (pills or injections).\n\nExclusion Criteria:\n\n1. Prior treatment with or known contraindication to treatment with tocilizumab or other IL-6/IL-6R targeted agent\n2. Patients who are PD-L1 positive (CPS \u2265 10), unless they have a clear contraindication to pembrolizumab therapy.\n3. Active infection requiring parenteral antibiotics\n4. Concurrent use of methotrexate or systemic corticosteroids\n5. Active or symptomatic CNS disease\n6. Patients with HER2+ disease HER2 will be considered positive if scored 3+ by immunohistochemistry (IHC) or 2+ by IHC associated with a fluorescence in situ hybridization (FISH) ratio of \\> 2.0 or \\> 6 total HER2 gene copies per cell.\n7. Patients with active malignancy other than breast cancer. Patients with prior malignancies without recurrence after standard treatment will not be excluded\n8. Radiation therapy within 2 weeks of registration\n9. Hormone therapy within 2 weeks of registration",
        "InclusionCriteria": "1. \u2265 18 years old at the time of informed consent\n2. Ability to provide written informed consent and HIPAA authorization\n3. Locally recurrent (not amenable to local therapy with curative intent) or metastatic breast cancer that is triple negative or ER-low (ER and PR \u2264 9% weak staining)\n4. No prior chemotherapy for metastatic disease\n\n   a. Prior (neo)adjuvant therapy must have been completed at least 12 months from diagnosis of unresectable locally recurrent or metastatic disease.\n5. Measurable disease based on RECIST 1.1 criteria.\n6. Disease amenable to and consent for study-specific biopsy\n\n   a. NOTE: If no disease amenable to biopsy is present at the time of second biopsy, subjects may continue participation in the study and further study specific biopsies will not be required.\n7. ECOG PS 0 or 1\n8. Patients with treated, asymptomatic CNS disease may participate if the patient is \\> 4 weeks from completion of CNS therapy (radiation and/or surgery), is clinically stable at the time of study entry, and is receiving a stable or decreasing dose of corticosteroid therapy. Brain MRI or head CT is required at screening for patients with known brain metastases.\n9. Adequate organ function as indicated by:\n\n   1. Total bilirubin \\< ULN (except in patients with documented Gilbert's disease, who must have a total bilirubin \\< 3.0 mg/dL)\n   2. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \\< 5.0 x ULN\n   3. Creatinine clearance of \\> 50 mL/min using the Cockcroft-Gault formula\n   4. Absolute neutrophil count (ANC) \\> 1.5 K/mm3\n   5. Platelets \\> 100 K/ mm3\n   6. Hgb \\> 9.0 g/dL\n10. Women of childbearing potential must have a negative pregnancy test within 14 days of protocol registration. Women are considered to have childbearing potential (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) unless they meet one of the following criteria:\n\n    1. Has undergone a hysterectomy or bilateral oophorectomy; or\n    2. Has been naturally amenorrheic for at least 24 consecutive months.\n11. Women of childbearing potential and men must agree to use effective contraception throughout the study and for 6 months after the last study treatment.\n\nNote: Acceptable methods of birth control include abstinence, partner with previous vasectomy, placement of an intrauterine device (IUD), condom with spermicidal foam/gel/film/cream/suppository, diaphragm or cervical vault cap, or hormonal birth control (pills or injections).",
        "ExclusionCriteria": "1. Prior treatment with or known contraindication to treatment with tocilizumab or other IL-6/IL-6R targeted agent\n2. Patients who are PD-L1 positive (CPS \u2265 10), unless they have a clear contraindication to pembrolizumab therapy.\n3. Active infection requiring parenteral antibiotics\n4. Concurrent use of methotrexate or systemic corticosteroids\n5. Active or symptomatic CNS disease\n6. Patients with HER2+ disease HER2 will be considered positive if scored 3+ by immunohistochemistry (IHC) or 2+ by IHC associated with a fluorescence in situ hybridization (FISH) ratio of \\> 2.0 or \\> 6 total HER2 gene copies per cell.\n7. Patients with active malignancy other than breast cancer. Patients with prior malignancies without recurrence after standard treatment will not be excluded\n8. Radiation therapy within 2 weeks of registration\n9. Hormone therapy within 2 weeks of registration",
        "HealthyVolunteers": false,
        "Gender": "ALL",
        "MinimumAge": "18 Years",
        "NCTId": "NCT05846789",
        "startDate": "",
        "completionDate": "",
        "durationDays": null,
        "daysUntilEnd": null
    },
    {
        "EligibilityCriteria": "Inclusion Criteria:\n\n* Subject is considered an adult according to local regulation at the time of signing the informed consent form (ICF).\n* Subject has measurable disease by RECIST Version 1.1.\n* Subject has accessible archival tumor tissue from either the primary tumor or a metastatic site, for which source and availability have been confirmed prior to study treatment. If no archival tumor tissue is available, the subject will have a biopsy to obtain tumor tissue prior to study treatment. If the subject is unable to undergo a biopsy due to safety concerns, enrollment into the study must be discussed with the medical monitor.\n* For cohort 9 only: Subject should submit archival or fresh tumor tissue sample for programmed cell death-ligand 1 (PD-L1) central testing during screening if no local PD-L1 test result is available. Central test result for PD-L1 will be required prior to subject enrollment. For cohort 9 subjects with local PD-L1 test result confirming CPS \u2265 1, archival or fresh tissue sample for exploratory analysis should be submitted within 5 days of enrollment.\n* Subject has ECOG performance status of 0 or 1.\n* Subject has the following baseline laboratory data. If a subject has received a recent blood transfusion, the hematology tests must be obtained \u2265 28 days after any blood transfusion.\n\n  * absolute neutrophil count (ANC) \u2265 1.0 \u00d7 10\\^9/L\n  * platelet count \u2265 100 \u00d7 10\\^9/L\n  * hemoglobin \u2265 9 g/dL\n  * serum total bilirubin \u2264 1.5 \u00d7 upper limit of normal (ULN) or \u2264 3 \u00d7 ULN for subjects with Gilbert's disease\n  * creatinine clearance (CrCl) \u2265 30 mL/min as estimated per institutional standards or as measured by 24-hour urine collection (glomerular filtration rate \\[GFR\\] can also be used instead of CrCl).\n  * alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \u2264 3 \u00d7 ULN\n* Subject agrees not to participate in another interventional study while receiving study treatment in the present study.\n* Additional contraceptive requirements exist for male and female subjects.\n\nDisease Specific Inclusion Criteria:\n\n* Evidence of progression on or after the last regimen received.\n* Locally advanced or metastatic disease that is not amenable to curative intent treatment.\n\nCohort 1: HR+/HER2- breast cancer\n\n* Subject has evidence of radiographic progression on or after the last regimen received.\n* Subject has histologically- or cytologically-confirmed HR+/HER2- (estrogen receptor \\[ER\\] positive and/or progesterone receptor \\[PR\\] positive, and HER2 negative) breast cancers and are not considered a candidate for further hormonal therapy. Subject will be considered HR+ if biopsies show \u2265 1% expression of ER or PR as per current American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines.\n* Subject has locally advanced or metastatic disease that is not amenable to curative intent treatment.\n* Subject must have received a taxane or anthracycline in the neoadjuvant, adjuvant or incurable, locally advanced or metastatic setting.\n\n  * Prior cytotoxic regimen received in the neoadjuvant or adjuvant setting will count as a prior cytotoxic regimen if disease recurrence occurred during or within 6 months of completing the regimen.\n* Subject has progressed, relapsed, or discontinued for toxicity during or after at least 1 prior standard of care cytotoxic regimen in the incurable, unresectable locally advanced or metastatic setting, and has not received \\> 2 prior lines of cytotoxic therapy in the locally advanced or metastatic setting. No limit applies to endocrine therapies. Poly(ADP-ribose) polymerases (PARP) inhibitors do not count as a line of cytotoxic therapy.\n* Subject has progressed, relapsed, or discontinued for toxicity during or after receiving endocrine therapy or with hormonally-directed therapy with cyclin-dependent kinase (CDK) inhibitors. Prior therapy with CDK inhibitors is not required.\n\nCohort 2: triple negative breast cancer (TNBC)\n\n* Subject has evidence of radiographic progression on or after the last regimen received.\n* Subject has histologically- or cytologically-confirmed TNBC; defined as unequivocal TNBC histology (ER-negative/PR-negative/HER2-negative). This is defined by \\< 1% expression of ER and PR by immunohistochemistry (IHC), and that are, for HER2, either 0 to 1+ by IHC, or IHC 2+ and fluorescence in situ hybridization (FISH) negative (not amplified) as per current ASCO/CAP guidelines.\n* Subject has locally advanced or metastatic disease that is not amenable to curative intent treatment.\n* Subject must have received a taxane or anthracycline in the neoadjuvant, adjuvant or incurable, locally advanced or metastatic setting.\n\n  * Prior cytotoxic regimen received in the neoadjuvant or adjuvant setting will count as a prior cytotoxic regimen if disease recurrence occurred during or within 6 months of completing the regimen.\n* Subject has progressed, relapsed, or discontinued for toxicity during or after at least 1 prior standard of care cytotoxic regimen in the incurable, unresectable locally advanced or metastatic setting, and has not received \\> 2 prior lines of cytotoxic therapy in the locally advanced or metastatic setting. Poly(ADP-ribose) polymerases (PARP) inhibitors do not count as a line of cytotoxic therapy.\n* Subject has received prior therapy with an anti-programmed cell death protein-1 (PD-1) or an anti-programmed cell death-ligand 1 (PD-L1) based on subject's tumor PD-1 or PD-L1 expression and local treatment guidelines and has progressed or discontinued treatment due to toxicity, or therapy is contraindicated for subject.\n\nCohort 3: squamous non-small cell lung cancer (NSCLC)\n\n* Subject has evidence of radiographic progression on or after the last regimen received.\n* Subject has histologically or cytologically-confirmed squamous NSCLC.\n\n  * Subjects with mixed histology NSCLC are eligible provided there is not any component of neuroendocrine histology.\n  * Subjects with known epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), reactive oxygen species (ROS), BRAF, or other actionable mutations are eligible if treated with mutation targeted therapy and have progressed, relapsed, or discontinued treatment due to toxicity.\n* Subject has locally advanced or metastatic disease that is not amenable to curative intent treatment.\n* Subject has progressed, relapsed, or discontinued treatment due to toxicity after 1 platinum-based standard of care regimen for locally advanced or metastatic disease, and has not received \\> 2 prior lines of cytotoxic anticancer therapy in the locally advanced or metastatic setting.\n\n  1. Subjects with locally advanced disease who previously received curative intent treatment with platinum-based standard of care regimen in the adjuvant or neoadjuvant setting or as part of concomitant chemoradiation therapy are eligible if they have progressed or relapsed within 6 months of completion.\n  2. Maintenance therapy does not constitute a new chemotherapy regimen provided there was no progression after the initial platinum-based regimen.\n  3. Changing chemotherapy agents during platinum-based treatment for the management of toxicities does not constitute a new chemotherapy regimen provided no progression had occurred while on the initial therapy.\n* Subject has received prior therapy with an anti-PD-1 or anti-PD-L1 based on subject's tumor PD-1 or PD-L1 expression and local treatment guidelines and has progressed, relapsed, or discontinued treatment due to toxicity, or therapy is contraindicated for subject.\n\nCohort 4: non-squamous non-small cell lung cancer\n\n* Subject has evidence of radiographic progression on or after the last regimen received.\n* Subject has histologically- or cytologically-confirmed non-squamous NSCLC.\n\n  * Subjects with mixed histology NSCLC are eligible provided there is not any component of neuroendocrine histology.\n  * Subjects with known EGFR, ALK, ROS, BRAF, or other actionable mutations are eligible if treated with mutation targeted therapy and have progressed, relapsed, or discontinued treatment due to toxicity.\n* Subject has locally advanced or metastatic disease that is not amenable to curative intent treatment.\n* Subject has progressed, relapsed, or discontinued treatment due to toxicity after 1 platinum-based standard of care regimen for locally advanced or metastatic disease, and has not received \\> 2 prior lines of cytotoxic anticancer therapy in the locally advanced or metastatic setting.\n\n  1. Subjects with locally advanced disease who previously received curative intent treatment with platinum-based standard of care regimen in the adjuvant or neoadjuvant setting or as part of concomitant chemoradiation therapy are eligible if they have progressed or relapsed within 6 months of completion.\n  2. Maintenance therapy does not constitute a new chemotherapy regimen provided there was no progression after the initial platinum-based regimen.\n  3. Changing chemotherapy agents during platinum-based treatment for the management of toxicities does not constitute a new chemotherapy regimen provided no progression has occurred while on the initial therapy.\n* Subject has received prior therapy with an anti-PD-1 or anti-PD-L1 based on subject's tumor PD-1 or PD-L1 expression and local treatment guidelines and has progressed, relapsed, or discontinued treatment due to toxicity, or therapy is contraindicated for subject.\n\nCohort 5: second-line or later head and neck cancer\n\n* Subject has evidence of radiographic progression on or after the last regimen received.\n* Subject has histologically- or cytologically-confirmed head and neck cancer.\n\n  * Primary tumor site must arise from the oral cavity, oropharynx, hypopharynx, and larynx; tumors arising from the nasopharynx are excluded. Salivary gland tumors and/or parotid gland tumors are not eligible for Cohort 5.\n* Subject has locally advanced or metastatic disease that is not amenable to curative intent treatment.\n* Subject has progressed, relapsed, or discontinued treatment due to toxicity after 1 platinum-based standard of care regimen for locally advanced or metastatic disease, and has not received \\> 2 prior lines of cytotoxic anticancer therapy in the locally advanced or metastatic setting.\n\n  * Subjects with locally advanced disease who previously received curative intent treatment with platinum-based standard of care regimen in the adjuvant or neoadjuvant setting or as part of concomitant chemoradiation therapy are eligible if they have progressed or relapsed within 6 months after completion.\n* Subject has received prior therapy with an anti-PD-1 or anti-PD-L1 based on subject's tumor PD-1 or PD-L1 expression and local treatment guidelines and has progressed, relapsed, or discontinued treatment due to toxicity, or therapy is contraindicated for subject.\n\nCohorts 6, 7 and 8: gastric or gastroesophageal junction (GEJ) or esophageal adenocarcinoma\n\n* Subject has evidence of radiographic progression on or after the last regimen received.\n* Subject has histologically- or cytologically-confirmed gastric, GEJ, or esophageal cancer.\n* Subject has locally advanced or metastatic disease that is not amenable to curative intent treatment.\n* Subject has progressed, relapsed, or discontinued due to toxicity after 1 platinum-based standard of care regimen for locally advanced or metastatic disease, and has not received \\> 2 prior lines of cytotoxic anticancer therapy in the locally advanced or metastatic setting.\n\n  * Neoadjuvant or adjuvant cytotoxic regimens will count as a prior regimen if relapsed or progressed \u2264 6 months after completion.\n* Subject must have received a HER2 directed therapy if known to have HER2 positive cancer.\n* Subject has received prior therapy with an anti-PD-1 or anti-PD-L1 based on subject's tumor PD-1 or PD-L1 expression and local treatment guidelines and has progressed, relapsed, or discontinued treatment due to toxicity, or therapy is contraindicated for subject.\n\nCohort 9: 1L HNSCC\n\n* Subject has histologically- or cytologically-confirmed head and neck squamous cell carcinoma.\n\n  a. Primary tumor site must arise from the oral cavity, oropharynx, hypopharynx, and larynx; tumors arising from the nasopharynx are excluded. Salivary gland tumors and/or parotid gland tumors are not eligible for Cohort 9.\n* Subject has recurrent or metastatic disease that is incurable by local therapies.\n* Subject's tumor sample has PD-L1 combined positive score (CPS) of \u2265 1 as determined by local or central IHC testing.\n* Subject has had no prior systemic therapy administered with the exception of systemic therapy completed \\> 6 months prior if given as part of multimodal treatment for locally advanced disease. Subjects who have received a PD-1 or PD-L1 inhibitor in the curative setting are eligible if it has been at least 12 months since last dose of the anti PD-L1 agent.\n* Subject has ANC \u2265 1.5 \u00d7 10\\^9/L.\n* International normalized ratio (INR) OR prothrombin time (PT) and activated partial thromboplastin (aPTT) both \u2264 1.5 \u00d7 ULN unless subject is receiving anticoagulant therapy as long as PT or aPTT is within the therapeutic range of intended use of anticoagulants. PTT may be used if local lab is unable to perform aPTT.\n* For subjects with oropharynx tumors, subject has results from testing of HPV status by p16 testing.\n\nExclusion Criteria:\n\nFor All Cohorts:\n\n* Subject has preexisting sensory or motor neuropathy Grade \u2265 2.\n* Subject has active central nervous system (CNS) metastases. Subjects with treated CNS metastases are permitted on study if all the following are true:\n\n  * CNS metastases have been clinically stable for \u2265 6 weeks prior to screening\n  * If requiring steroid treatment for CNS metastases, the subject is on a stable dose \u2264 20 mg/day of prednisone or equivalent for \u2265 2 weeks\n  * Baseline imaging scans show no evidence of new or enlarged brain metastasis\n  * Subject does not have leptomeningeal disease\n* Subject has ongoing clinically significant toxicity (Grade 2 or higher with the exception of alopecia) associated with prior treatment (including systemic therapy, radiotherapy or surgery).\n* Subjects with ongoing \u2265 Grade 3 immunotherapy-related hypothyroidism or panhypopituitarism are excluded. Subjects with ongoing immunotherapy-related colitis, uveitis, myocarditis or pneumonitis, or subjects with other immunotherapy-related AEs requiring high doses of steroids (\\> 20 mg/day of prednisone or equivalent), are excluded. Subject with \u2264 Grade 2 immunotherapy-related hypothyroidism or panhypopituitarism may be enrolled when well maintained/controlled on a stable dose of hormone replacement therapy (if indicated).\n* Subject has a history of uncontrolled diabetes mellitus within 3 months before the first dose of study treatment. Uncontrolled diabetes (within 3 months before first dose) is defined as hemoglobin A1c (HbA1c) \u2265 8% or HbA1c between 7 and \\< 8% with associated diabetes symptoms (polyuria or polydipsia) that are not otherwise explained. The lowest HbA1c during the screening period will be used to determine eligibility.\n* Subject has prior treatment with enfortumab vedotin or other monomethyl auristatin E (MMAE) based antibody-drug conjugates (ADCs).\n* Subject has a second malignancy diagnosed within 3 years before first dose of study drug, or any evidence of residual disease from a previously diagnosed malignancy. Subjects with non-melanoma skin cancer, localized prostate cancer treated with curative intent with no evidence of progression, low-risk or very low-risk (per standard guidelines) localized prostate cancer under active surveillance/watchful waiting without intent to treat, or carcinoma in situ of any type (if complete resection was performed) are allowed.\n* Subject is currently receiving systemic antimicrobial treatment for viral, bacterial, or fungal infection at the time of first dose of study treatment. Routine antimicrobial prophylaxis is permitted.\n* Subject has known active hepatitis B (e.g., hepatitis B surface antigen \\[HBsAg\\] reactive) or active hepatitis C (e.g., hepatitis C virus \\[HCV\\] RNA \\[qualitative\\] is detected).\n* Subject has known history of human immunodeficiency virus (HIV) infection (HIV 1 or 2).\n* Subject has documented history of a cerebral vascular event (stroke or transient ischemic attack), unstable angina, myocardial infarction or cardiac symptoms (including congestive heart failure) consistent with New York Heart Association Class III-IV within 6 months prior to the first dose of study drug.\n* Subject has major surgery within 4 weeks prior to first dose of study drug.\n* Subject had radiotherapy, chemotherapy, biologics, investigational agents, and/or antitumor treatment with immunotherapy that is not completed 2 weeks prior to first dose of study drug.\n* Subject has known hypersensitivity to enfortumab vedotin or to any excipient contained in the drug formulation of enfortumab vedotin (including histidine, trehalose dihydrate and polysorbate 20) OR subject has known hypersensitivity to biopharmaceutical produced in Chinese hamster ovary cells.\n* Subject has known active keratitis or corneal ulcerations. Subject with superficial punctate keratitis is allowed if the disorder is being adequately treated.\n* Subject has any condition which makes the subject unsuitable for study participation.\n\nCohort 9: 1L HNSCC\n\n* Had PD within 6 months of completion of curatively intended systemic treatment for locoregionally advanced HNSCC.\n* Has had an allogeneic tissue/solid organ transplant. Has severe hypersensitivity (\u2265grade 3) to pembrolizumab and/or any of its excipients.\n* Has a history of (non-infectious) pneumonitis / interstitial lung disease that required steroids or has current pneumonitis / interstitial lung disease.\n* Has a history of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan.\n* Has a life expectancy of less than 3 months and/or has rapidly progressing disease (e.g. tumor bleeding, uncontrolled tumor pain) in the opinion of the treating investigator.\n* Active autoimmune disease that has required systemic treatment in past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs).\n\n  1. Replacement therapy (e.g., thyroxine, insulin, physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed.\n  2. Brief (\\<7 days) use of systemic corticosteroids is allowed when use is considered standard of care.\n  3. Subjects with vitiligo, psoriasis, type 1 diabetes mellitus, hypothyroidism, or resolved childhood asthma/atopy will not be excluded.\n  4. Subjects requiring intermittent use of bronchodilators, inhaled steroids, or local steroid injections will not be excluded.\n  5. Subjects with hypothyroidism that is stable with hormone replacement or Sj\u00f6gren's syndrome will not be excluded.\n* Has an active infection requiring systemic therapy.\n* Has received prior therapy with an anti-PD-1 or anti-PD-L1 agent in the recurrent/metastatic setting. If anti-PD-1 or anti-PD-L1 agent was given as part of curative intent therapy, it must be at least 1 year since last dose.\n* Has received a live vaccine within 30 days of planned start of study therapy. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette Gu\u00e9rin, and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g., FluMist\u00ae) are live attenuated vaccines and are not allowed.\n* Subject has active tuberculosis",
        "InclusionCriteria": "* Evidence of progression on or after the last regimen received.\n* Locally advanced or metastatic disease that is not amenable to curative intent treatment.\n\nCohort 1: HR+/HER2- breast cancer\n\n* Subject has evidence of radiographic progression on or after the last regimen received.\n* Subject has histologically- or cytologically-confirmed HR+/HER2- (estrogen receptor \\[ER\\] positive and/or progesterone receptor \\[PR\\] positive, and HER2 negative) breast cancers and are not considered a candidate for further hormonal therapy. Subject will be considered HR+ if biopsies show \u2265 1% expression of ER or PR as per current American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines.\n* Subject has locally advanced or metastatic disease that is not amenable to curative intent treatment.\n* Subject must have received a taxane or anthracycline in the neoadjuvant, adjuvant or incurable, locally advanced or metastatic setting.\n\n  * Prior cytotoxic regimen received in the neoadjuvant or adjuvant setting will count as a prior cytotoxic regimen if disease recurrence occurred during or within 6 months of completing the regimen.\n* Subject has progressed, relapsed, or discontinued for toxicity during or after at least 1 prior standard of care cytotoxic regimen in the incurable, unresectable locally advanced or metastatic setting, and has not received \\> 2 prior lines of cytotoxic therapy in the locally advanced or metastatic setting. No limit applies to endocrine therapies. Poly(ADP-ribose) polymerases (PARP) inhibitors do not count as a line of cytotoxic therapy.\n* Subject has progressed, relapsed, or discontinued for toxicity during or after receiving endocrine therapy or with hormonally-directed therapy with cyclin-dependent kinase (CDK) inhibitors. Prior therapy with CDK inhibitors is not required.\n\nCohort 2: triple negative breast cancer (TNBC)\n\n* Subject has evidence of radiographic progression on or after the last regimen received.\n* Subject has histologically- or cytologically-confirmed TNBC; defined as unequivocal TNBC histology (ER-negative/PR-negative/HER2-negative). This is defined by \\< 1% expression of ER and PR by immunohistochemistry (IHC), and that are, for HER2, either 0 to 1+ by IHC, or IHC 2+ and fluorescence in situ hybridization (FISH) negative (not amplified) as per current ASCO/CAP guidelines.\n* Subject has locally advanced or metastatic disease that is not amenable to curative intent treatment.\n* Subject must have received a taxane or anthracycline in the neoadjuvant, adjuvant or incurable, locally advanced or metastatic setting.\n\n  * Prior cytotoxic regimen received in the neoadjuvant or adjuvant setting will count as a prior cytotoxic regimen if disease recurrence occurred during or within 6 months of completing the regimen.\n* Subject has progressed, relapsed, or discontinued for toxicity during or after at least 1 prior standard of care cytotoxic regimen in the incurable, unresectable locally advanced or metastatic setting, and has not received \\> 2 prior lines of cytotoxic therapy in the locally advanced or metastatic setting. Poly(ADP-ribose) polymerases (PARP) inhibitors do not count as a line of cytotoxic therapy.\n* Subject has received prior therapy with an anti-programmed cell death protein-1 (PD-1) or an anti-programmed cell death-ligand 1 (PD-L1) based on subject's tumor PD-1 or PD-L1 expression and local treatment guidelines and has progressed or discontinued treatment due to toxicity, or therapy is contraindicated for subject.\n\nCohort 3: squamous non-small cell lung cancer (NSCLC)\n\n* Subject has evidence of radiographic progression on or after the last regimen received.\n* Subject has histologically or cytologically-confirmed squamous NSCLC.\n\n  * Subjects with mixed histology NSCLC are eligible provided there is not any component of neuroendocrine histology.\n  * Subjects with known epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), reactive oxygen species (ROS), BRAF, or other actionable mutations are eligible if treated with mutation targeted therapy and have progressed, relapsed, or discontinued treatment due to toxicity.\n* Subject has locally advanced or metastatic disease that is not amenable to curative intent treatment.\n* Subject has progressed, relapsed, or discontinued treatment due to toxicity after 1 platinum-based standard of care regimen for locally advanced or metastatic disease, and has not received \\> 2 prior lines of cytotoxic anticancer therapy in the locally advanced or metastatic setting.\n\n  1. Subjects with locally advanced disease who previously received curative intent treatment with platinum-based standard of care regimen in the adjuvant or neoadjuvant setting or as part of concomitant chemoradiation therapy are eligible if they have progressed or relapsed within 6 months of completion.\n  2. Maintenance therapy does not constitute a new chemotherapy regimen provided there was no progression after the initial platinum-based regimen.\n  3. Changing chemotherapy agents during platinum-based treatment for the management of toxicities does not constitute a new chemotherapy regimen provided no progression had occurred while on the initial therapy.\n* Subject has received prior therapy with an anti-PD-1 or anti-PD-L1 based on subject's tumor PD-1 or PD-L1 expression and local treatment guidelines and has progressed, relapsed, or discontinued treatment due to toxicity, or therapy is contraindicated for subject.\n\nCohort 4: non-squamous non-small cell lung cancer\n\n* Subject has evidence of radiographic progression on or after the last regimen received.\n* Subject has histologically- or cytologically-confirmed non-squamous NSCLC.\n\n  * Subjects with mixed histology NSCLC are eligible provided there is not any component of neuroendocrine histology.\n  * Subjects with known EGFR, ALK, ROS, BRAF, or other actionable mutations are eligible if treated with mutation targeted therapy and have progressed, relapsed, or discontinued treatment due to toxicity.\n* Subject has locally advanced or metastatic disease that is not amenable to curative intent treatment.\n* Subject has progressed, relapsed, or discontinued treatment due to toxicity after 1 platinum-based standard of care regimen for locally advanced or metastatic disease, and has not received \\> 2 prior lines of cytotoxic anticancer therapy in the locally advanced or metastatic setting.\n\n  1. Subjects with locally advanced disease who previously received curative intent treatment with platinum-based standard of care regimen in the adjuvant or neoadjuvant setting or as part of concomitant chemoradiation therapy are eligible if they have progressed or relapsed within 6 months of completion.\n  2. Maintenance therapy does not constitute a new chemotherapy regimen provided there was no progression after the initial platinum-based regimen.\n  3. Changing chemotherapy agents during platinum-based treatment for the management of toxicities does not constitute a new chemotherapy regimen provided no progression has occurred while on the initial therapy.\n* Subject has received prior therapy with an anti-PD-1 or anti-PD-L1 based on subject's tumor PD-1 or PD-L1 expression and local treatment guidelines and has progressed, relapsed, or discontinued treatment due to toxicity, or therapy is contraindicated for subject.\n\nCohort 5: second-line or later head and neck cancer\n\n* Subject has evidence of radiographic progression on or after the last regimen received.\n* Subject has histologically- or cytologically-confirmed head and neck cancer.\n\n  * Primary tumor site must arise from the oral cavity, oropharynx, hypopharynx, and larynx; tumors arising from the nasopharynx are excluded. Salivary gland tumors and/or parotid gland tumors are not eligible for Cohort 5.\n* Subject has locally advanced or metastatic disease that is not amenable to curative intent treatment.\n* Subject has progressed, relapsed, or discontinued treatment due to toxicity after 1 platinum-based standard of care regimen for locally advanced or metastatic disease, and has not received \\> 2 prior lines of cytotoxic anticancer therapy in the locally advanced or metastatic setting.\n\n  * Subjects with locally advanced disease who previously received curative intent treatment with platinum-based standard of care regimen in the adjuvant or neoadjuvant setting or as part of concomitant chemoradiation therapy are eligible if they have progressed or relapsed within 6 months after completion.\n* Subject has received prior therapy with an anti-PD-1 or anti-PD-L1 based on subject's tumor PD-1 or PD-L1 expression and local treatment guidelines and has progressed, relapsed, or discontinued treatment due to toxicity, or therapy is contraindicated for subject.\n\nCohorts 6, 7 and 8: gastric or gastroesophageal junction (GEJ) or esophageal adenocarcinoma\n\n* Subject has evidence of radiographic progression on or after the last regimen received.\n* Subject has histologically- or cytologically-confirmed gastric, GEJ, or esophageal cancer.\n* Subject has locally advanced or metastatic disease that is not amenable to curative intent treatment.\n* Subject has progressed, relapsed, or discontinued due to toxicity after 1 platinum-based standard of care regimen for locally advanced or metastatic disease, and has not received \\> 2 prior lines of cytotoxic anticancer therapy in the locally advanced or metastatic setting.\n\n  * Neoadjuvant or adjuvant cytotoxic regimens will count as a prior regimen if relapsed or progressed \u2264 6 months after completion.\n* Subject must have received a HER2 directed therapy if known to have HER2 positive cancer.\n* Subject has received prior therapy with an anti-PD-1 or anti-PD-L1 based on subject's tumor PD-1 or PD-L1 expression and local treatment guidelines and has progressed, relapsed, or discontinued treatment due to toxicity, or therapy is contraindicated for subject.\n\nCohort 9: 1L HNSCC\n\n* Subject has histologically- or cytologically-confirmed head and neck squamous cell carcinoma.\n\n  a. Primary tumor site must arise from the oral cavity, oropharynx, hypopharynx, and larynx; tumors arising from the nasopharynx are excluded. Salivary gland tumors and/or parotid gland tumors are not eligible for Cohort 9.\n* Subject has recurrent or metastatic disease that is incurable by local therapies.\n* Subject's tumor sample has PD-L1 combined positive score (CPS) of \u2265 1 as determined by local or central IHC testing.\n* Subject has had no prior systemic therapy administered with the exception of systemic therapy completed \\> 6 months prior if given as part of multimodal treatment for locally advanced disease. Subjects who have received a PD-1 or PD-L1 inhibitor in the curative setting are eligible if it has been at least 12 months since last dose of the anti PD-L1 agent.\n* Subject has ANC \u2265 1.5 \u00d7 10\\^9/L.\n* International normalized ratio (INR) OR prothrombin time (PT) and activated partial thromboplastin (aPTT) both \u2264 1.5 \u00d7 ULN unless subject is receiving anticoagulant therapy as long as PT or aPTT is within the therapeutic range of intended use of anticoagulants. PTT may be used if local lab is unable to perform aPTT.\n* For subjects with oropharynx tumors, subject has results from testing of HPV status by p16 testing.",
        "ExclusionCriteria": "For All Cohorts:\n\n* Subject has preexisting sensory or motor neuropathy Grade \u2265 2.\n* Subject has active central nervous system (CNS) metastases. Subjects with treated CNS metastases are permitted on study if all the following are true:\n\n  * CNS metastases have been clinically stable for \u2265 6 weeks prior to screening\n  * If requiring steroid treatment for CNS metastases, the subject is on a stable dose \u2264 20 mg/day of prednisone or equivalent for \u2265 2 weeks\n  * Baseline imaging scans show no evidence of new or enlarged brain metastasis\n  * Subject does not have leptomeningeal disease\n* Subject has ongoing clinically significant toxicity (Grade 2 or higher with the exception of alopecia) associated with prior treatment (including systemic therapy, radiotherapy or surgery).\n* Subjects with ongoing \u2265 Grade 3 immunotherapy-related hypothyroidism or panhypopituitarism are excluded. Subjects with ongoing immunotherapy-related colitis, uveitis, myocarditis or pneumonitis, or subjects with other immunotherapy-related AEs requiring high doses of steroids (\\> 20 mg/day of prednisone or equivalent), are excluded. Subject with \u2264 Grade 2 immunotherapy-related hypothyroidism or panhypopituitarism may be enrolled when well maintained/controlled on a stable dose of hormone replacement therapy (if indicated).\n* Subject has a history of uncontrolled diabetes mellitus within 3 months before the first dose of study treatment. Uncontrolled diabetes (within 3 months before first dose) is defined as hemoglobin A1c (HbA1c) \u2265 8% or HbA1c between 7 and \\< 8% with associated diabetes symptoms (polyuria or polydipsia) that are not otherwise explained. The lowest HbA1c during the screening period will be used to determine eligibility.\n* Subject has prior treatment with enfortumab vedotin or other monomethyl auristatin E (MMAE) based antibody-drug conjugates (ADCs).\n* Subject has a second malignancy diagnosed within 3 years before first dose of study drug, or any evidence of residual disease from a previously diagnosed malignancy. Subjects with non-melanoma skin cancer, localized prostate cancer treated with curative intent with no evidence of progression, low-risk or very low-risk (per standard guidelines) localized prostate cancer under active surveillance/watchful waiting without intent to treat, or carcinoma in situ of any type (if complete resection was performed) are allowed.\n* Subject is currently receiving systemic antimicrobial treatment for viral, bacterial, or fungal infection at the time of first dose of study treatment. Routine antimicrobial prophylaxis is permitted.\n* Subject has known active hepatitis B (e.g., hepatitis B surface antigen \\[HBsAg\\] reactive) or active hepatitis C (e.g., hepatitis C virus \\[HCV\\] RNA \\[qualitative\\] is detected).\n* Subject has known history of human immunodeficiency virus (HIV) infection (HIV 1 or 2).\n* Subject has documented history of a cerebral vascular event (stroke or transient ischemic attack), unstable angina, myocardial infarction or cardiac symptoms (including congestive heart failure) consistent with New York Heart Association Class III-IV within 6 months prior to the first dose of study drug.\n* Subject has major surgery within 4 weeks prior to first dose of study drug.\n* Subject had radiotherapy, chemotherapy, biologics, investigational agents, and/or antitumor treatment with immunotherapy that is not completed 2 weeks prior to first dose of study drug.\n* Subject has known hypersensitivity to enfortumab vedotin or to any excipient contained in the drug formulation of enfortumab vedotin (including histidine, trehalose dihydrate and polysorbate 20) OR subject has known hypersensitivity to biopharmaceutical produced in Chinese hamster ovary cells.\n* Subject has known active keratitis or corneal ulcerations. Subject with superficial punctate keratitis is allowed if the disorder is being adequately treated.\n* Subject has any condition which makes the subject unsuitable for study participation.\n\nCohort 9: 1L HNSCC\n\n* Had PD within 6 months of completion of curatively intended systemic treatment for locoregionally advanced HNSCC.\n* Has had an allogeneic tissue/solid organ transplant. Has severe hypersensitivity (\u2265grade 3) to pembrolizumab and/or any of its excipients.\n* Has a history of (non-infectious) pneumonitis / interstitial lung disease that required steroids or has current pneumonitis / interstitial lung disease.\n* Has a history of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan.\n* Has a life expectancy of less than 3 months and/or has rapidly progressing disease (e.g. tumor bleeding, uncontrolled tumor pain) in the opinion of the treating investigator.\n* Active autoimmune disease that has required systemic treatment in past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs).\n\n  1. Replacement therapy (e.g., thyroxine, insulin, physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed.\n  2. Brief (\\<7 days) use of systemic corticosteroids is allowed when use is considered standard of care.\n  3. Subjects with vitiligo, psoriasis, type 1 diabetes mellitus, hypothyroidism, or resolved childhood asthma/atopy will not be excluded.\n  4. Subjects requiring intermittent use of bronchodilators, inhaled steroids, or local steroid injections will not be excluded.\n  5. Subjects with hypothyroidism that is stable with hormone replacement or Sj\u00f6gren's syndrome will not be excluded.\n* Has an active infection requiring systemic therapy.\n* Has received prior therapy with an anti-PD-1 or anti-PD-L1 agent in the recurrent/metastatic setting. If anti-PD-1 or anti-PD-L1 agent was given as part of curative intent therapy, it must be at least 1 year since last dose.\n* Has received a live vaccine within 30 days of planned start of study therapy. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette Gu\u00e9rin, and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g., FluMist\u00ae) are live attenuated vaccines and are not allowed.\n* Subject has active tuberculosis",
        "HealthyVolunteers": false,
        "Gender": "ALL",
        "MinimumAge": "18 Years",
        "NCTId": "NCT04225117",
        "startDate": "",
        "completionDate": "",
        "durationDays": null,
        "daysUntilEnd": null
    },
    {
        "EligibilityCriteria": "Inclusion Criteria:\n\n* Participants must have one of the following histologically or cytologically confirmed locally advanced unresectable or metastatic solid tumor types:\n\n  * High-grade serous epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer\n  * HER2-negative, HR positive breast cancer\n  * Triple-negative breast cancer (TNBC)\n  * Endometrial carcinoma\n  * Non-small cell lung cancer (Squamous cell carcinoma \\[SqCC\\], Adenocarcinoma \\[AC\\])\n  * Cholangiocarcinoma or gallbladder carcinoma\n  * Adenoid cystic carcinoma (ACC)\n* Parts A and B: Participants must have disease that is relapsed or refractory or be intolerant to SOC therapies, and, in the judgement of the investigator, should have no appropriate SOC therapeutic option\n* Part C: Participants must have disease that is relapsed or refractory or be intolerant to SOC therapies, unless contraindicated\n* Tumor tissue is required for enrollment.\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1\n* Measurable disease per RECIST version 1.1 at baseline\n\nExclusion Criteria:\n\n* History of another malignancy within 3 years before the first dose of study drug. Any evidence of residual disease from a previously diagnosed malignancy. Exceptions are malignancies with a negligible risk of metastasis or death.\n* Known active central nervous system metastases. Participants with previously treated brain metastases may participate provided they:\n\n  * are clinically stable for at least 4 weeks prior to study entry after brain metastasis treatment\n  * have no new or enlarging brain metastases\n  * and are off corticosteroids prescribed for symptoms associated with brain metastases for at least 7 days prior to the first dose of study treatment.\n* Carcinomatous meningitis\n* Previous receipt of an MMAE-containing agent or an agent targeting B7-H4\n* Pre-existing neuropathy \u2265 Grade 2 per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0\n* Corneal disease or injury requiring treatment or active monitoring",
        "InclusionCriteria": "* Participants must have one of the following histologically or cytologically confirmed locally advanced unresectable or metastatic solid tumor types:\n\n  * High-grade serous epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer\n  * HER2-negative, HR positive breast cancer\n  * Triple-negative breast cancer (TNBC)\n  * Endometrial carcinoma\n  * Non-small cell lung cancer (Squamous cell carcinoma \\[SqCC\\], Adenocarcinoma \\[AC\\])\n  * Cholangiocarcinoma or gallbladder carcinoma\n  * Adenoid cystic carcinoma (ACC)\n* Parts A and B: Participants must have disease that is relapsed or refractory or be intolerant to SOC therapies, and, in the judgement of the investigator, should have no appropriate SOC therapeutic option\n* Part C: Participants must have disease that is relapsed or refractory or be intolerant to SOC therapies, unless contraindicated\n* Tumor tissue is required for enrollment.\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1\n* Measurable disease per RECIST version 1.1 at baseline",
        "ExclusionCriteria": "* History of another malignancy within 3 years before the first dose of study drug. Any evidence of residual disease from a previously diagnosed malignancy. Exceptions are malignancies with a negligible risk of metastasis or death.\n* Known active central nervous system metastases. Participants with previously treated brain metastases may participate provided they:\n\n  * are clinically stable for at least 4 weeks prior to study entry after brain metastasis treatment\n  * have no new or enlarging brain metastases\n  * and are off corticosteroids prescribed for symptoms associated with brain metastases for at least 7 days prior to the first dose of study treatment.\n* Carcinomatous meningitis\n* Previous receipt of an MMAE-containing agent or an agent targeting B7-H4\n* Pre-existing neuropathy \u2265 Grade 2 per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0\n* Corneal disease or injury requiring treatment or active monitoring",
        "HealthyVolunteers": false,
        "Gender": "ALL",
        "MinimumAge": "18 Years",
        "NCTId": "NCT05194072",
        "startDate": "",
        "completionDate": "",
        "durationDays": null,
        "daysUntilEnd": null
    },
    {
        "EligibilityCriteria": "General Inclusion Criteria\n\n* Written informed consent and HIPAA authorization for release of personal health information. NOTE: HIPAA authorization may be included in the informed consent or may be obtained separately.\n* Age \u2265 18 years at the time of consent.\n* ECOG Performance Status 0 or 1 within 28 days prior to study registration.\n* Must have histologically or cytologically confirmed triple negative (ER-/PR-/HER2-) invasive breast cancer per pathology report. NOTE: ER and PR will be considered negative if \u2264 10% of cells stain weakly positive. HER2 will be considered negative if scored 0 or 1+ by immunohistochemistry (IHC) or 2+ by IHC associated with a fluorescence in situ hybridization (FISH) ratio of \\< 2.0 or \\< 6 copies per cell.\n* Must have clinical stage I-III at diagnosis (AJCC 8th edition) based on initial evaluation by physical examination and/or breast imaging prior to neoadjuvant chemotherapy.\n* Must have completed preoperative (neoadjuvant) chemotherapy for this index case. NOTE: Acceptable preoperative regimens include an anthracycline or a taxane, or both. Participants who received preoperative therapy as part of a clinical trial may enroll. Participants may not have received adjuvant chemotherapy after surgery prior to registration. Bisphosphonate use is allowed.\n* Subjects who received pembrolizumab in the neoadjuvant setting are eligible and may continue treatment during the screening process. Subjects assigned to Arm 1 will require a 3 week wash out period prior to initiation of study treatment. Subjects may resume pembrolizumab to complete the planned year of therapy (17 cycles) after completion of study therapy based on investigator discretion. Subjects assigned to Arm 2 and Arm 3 may continue pembrolizumab treatment during the study based on investigator discretion. Total duration of pembrolizumab treatment should not be extended beyond 17 cycles.\n* Must have significant residual invasive disease at the time of definitive surgery following preoperative chemotherapy. Significant residual disease is defined as at least one of the following:\n\n  * Residual invasive disease in the breast measuring at least 1 cm. The presence of DCIS without invasion does not qualify as residual disease in the breast.\n  * Any macroscopic, (\u2265 2mm) residual, lymph node involvement regardless of primary tumor site involvement (includes no residual disease in the breast).\n  * Residual cancer burden (RCB) score 2 or 3.\n* Must have completed definitive resection of primary tumor. Participants must begin assigned arm therapy no later than 96 days from the last local therapy. NOTE: Negative margins for both invasive and ductal carcinoma in situ (DCIS) are desirable, however participants with positive margins may enroll if the study site treatment team believes no further surgery is possible and participant has received radiotherapy. Participants with margins positive for lobular carcinoma in situ (LCIS) are eligible. Either mastectomy or breast conserving surgery (including lumpectomy or partial mastectomy) is acceptable.\n* Breast Radiotherapy\n\n  * Radiotherapy is required for participants who underwent breast-conserving therapy, including lumpectomy or partial mastectomy unless deemed inappropriate by the treating provider.\n  * Post mastectomy radiation is at the discretion of the treating physician.\n  * If radiation was given prior to surgery, additional radiation after surgery is not required.\n  * In all cases participants must begin arm assigned therapy no later than 96 days from the last local therapy\n  * Any acute toxicity must have resolved to grade \\< 2 prior to starting arm specific therapy.\n* Must consent to allow submission of blood and archived tumor tissue sample from definitive surgery for next generation sequencing of the tumor. Tumor block is preferred however 14 slides + 1H\\&E can be submitted if necessary. NOTE: Due to possible false positives, ctDNA should not be drawn before completing radiation or less than 14 days from surgery if radiation is not required.\n* Adequate laboratory values must be obtained within 28 days prior to study registration.\n\n  * Hemoglobin (Hgb) \u2265 9.0 g/dL\n  * Platelets \u2265 100 K/mm3\n  * Absolute neutrophil count (ANC) \u2265 1.5 K/mm3\n  * Calculated creatinine clearance of \u2265 50 cc/min using the Cockcroft-Gault formula\n  * Bilirubin \u2264 1.5 ULN (except in participants with documented Gilbert's disease, who must have a total bilirubin \u2264 3.0 mg/dL)\n  * Aspartate aminotransferase (AST, SGOT) \u2264 2.5 ULN\n  * Alanine aminotransferase (ALT, SGPT) \u2264 2.5 ULN\n* Women of childbearing potential and their partners and male subjects and their partners must be willing to use effective contraception (as outlined in protocol) from the time consent is signed until after protocol therapy discontinuation based on package insert or investigator brochure guidelines (See protocol for timeframes).\n* Women of childbearing potential must have a negative urine or serum pregnancy test at screening and within 7 days prior to study registration. Women should be counseled regarding acceptable birth control methods to utilize. If prior to treatment after discussion with the subject it is felt by the treating physician there is a possibility the subject is pregnant a pregnancy test should be repeated. NOTE: Women are considered not of childbearing potential if they are surgically sterile (they have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy), or they are postmenopausal for at least 12 consecutive months.\n* Women must not be breastfeeding from the time of treatment initiation until the number of days after protocol therapy discontinuation based on package insert or investigator brochure guidelines (See protocol for timeframes).\n\nInclusion Criteria for Patients Assigned to Arm 1c ONLY\n\n-Adequate laboratory values must be obtained within 21 days prior to starting arm therapy.\n\n* Fasting total glucose \u2264 126 mg/dL\n* HbA1C \u2264 5.7%\n* Cholesterol \\< 300 mg/dL; 10.34 mmol/L\n* Triglycerides \\< 300 mg/dL; 3.42 mmol/L\n\nGeneral Exclusion Criteria\n\n* Clinically significant infections as judged by the treating physician.\n* Stage IV (metastatic) disease, however no specific staging studies are required in the absence of symptoms or physical exam findings that would suggest distant disease.\n* HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of registration are eligible for this trial. NOTE: Patients without a known history of being HIV positive do not require testing at screening. Patients who are known to be HIV positive will require testing as described to be eligible for this trial. Testing should be considered standard of care.\n* Patients with evidence of chronic hepatitis B virus (HBV) infection, with undetectable HBV viral load within 6 months of registration are eligible for this trial. They should be on suppressive therapy, if indicated. Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, the HCV viral load must be undetectable within 6 months of registration to be eligible for this trial. NOTE: Patients without a known history of being hepatitis positive do not require testing at screening. Patients who are known to be hepatitis positive will require testing as described to be eligible for this trial. Testing should be considered standard of care.\n* Participants with unstable angina or a myocardial infarction within 12 months of study registration.\n* Active second malignancy (except non-melanomatous skin cancer or incidental prostate cancer found on cystectomy): Active second malignancy is defined as a current need for cancer therapy or a high possibility (\\> 30%) of recurrence during the study. Previous contralateral breast cancer is allowable unless it meets \"active\" criteria as stated above.\n* Inability to swallow pills.\n* Evidence of significant uncontrolled concomitant disease that could affect compliance with the protocol, safety of participation, or interpretation of results. This includes significant liver disease (such as cirrhosis, uncontrolled major seizure disorder, or superior vena cava syndrome) or any other serious medical condition or abnormality in clinical laboratory tests that meet these criteria in the investigator's opinion.\n* History of severe allergic, anaphylactic, or other hypersensitivity reactions to any of the study medications being used in this study.\n* Treatment with any investigational agent within 30 days prior to study registration.\n\nExclusion Criteria for Patients Assigned to Arm 1c ONLY\n\n* Any concurrent ocular or intraocular condition (e.g., cataract or diabetic retinopathy) that, in the opinion of the investigator, would require medical or surgical intervention during the study period to prevent or treat vision loss that might result from that condition.\n* Type 2 diabetes requiring ongoing systemic treatment at the time of study entry; or any history of Type 1 diabetes.\n* Active inflammatory (e.g., uveitis or vitritis) or infectious (e.g., conjunctivitis, keratitis, scleritis, or endophthalmitis) conditions in either eye or history of idiopathic or autoimmune-associated uveitis in either eye.\n* Symptomatic active lung disease, including pneumonitis\n* History of or active inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis). Patients currently receiving immunosuppressants for inflammatory bowel disease (e.g., sulfasalazine) are considered to have active disease and are therefore ineligible.\n* Any active bowel inflammation (including diverticulitis)\n* Symptomatic hypercalcemia requiring continued use of bisphosphonate or denosumab therapy. Bisphosphonate and denosumab therapy for bone metastases or osteopenia/osteoporosis is allowed.",
        "InclusionCriteria": "* Written informed consent and HIPAA authorization for release of personal health information. NOTE: HIPAA authorization may be included in the informed consent or may be obtained separately.\n* Age \u2265 18 years at the time of consent.\n* ECOG Performance Status 0 or 1 within 28 days prior to study registration.\n* Must have histologically or cytologically confirmed triple negative (ER-/PR-/HER2-) invasive breast cancer per pathology report. NOTE: ER and PR will be considered negative if \u2264 10% of cells stain weakly positive. HER2 will be considered negative if scored 0 or 1+ by immunohistochemistry (IHC) or 2+ by IHC associated with a fluorescence in situ hybridization (FISH) ratio of \\< 2.0 or \\< 6 copies per cell.\n* Must have clinical stage I-III at diagnosis (AJCC 8th edition) based on initial evaluation by physical examination and/or breast imaging prior to neoadjuvant chemotherapy.\n* Must have completed preoperative (neoadjuvant) chemotherapy for this index case. NOTE: Acceptable preoperative regimens include an anthracycline or a taxane, or both. Participants who received preoperative therapy as part of a clinical trial may enroll. Participants may not have received adjuvant chemotherapy after surgery prior to registration. Bisphosphonate use is allowed.\n* Subjects who received pembrolizumab in the neoadjuvant setting are eligible and may continue treatment during the screening process. Subjects assigned to Arm 1 will require a 3 week wash out period prior to initiation of study treatment. Subjects may resume pembrolizumab to complete the planned year of therapy (17 cycles) after completion of study therapy based on investigator discretion. Subjects assigned to Arm 2 and Arm 3 may continue pembrolizumab treatment during the study based on investigator discretion. Total duration of pembrolizumab treatment should not be extended beyond 17 cycles.\n* Must have significant residual invasive disease at the time of definitive surgery following preoperative chemotherapy. Significant residual disease is defined as at least one of the following:\n\n  * Residual invasive disease in the breast measuring at least 1 cm. The presence of DCIS without invasion does not qualify as residual disease in the breast.\n  * Any macroscopic, (\u2265 2mm) residual, lymph node involvement regardless of primary tumor site involvement (includes no residual disease in the breast).\n  * Residual cancer burden (RCB) score 2 or 3.\n* Must have completed definitive resection of primary tumor. Participants must begin assigned arm therapy no later than 96 days from the last local therapy. NOTE: Negative margins for both invasive and ductal carcinoma in situ (DCIS) are desirable, however participants with positive margins may enroll if the study site treatment team believes no further surgery is possible and participant has received radiotherapy. Participants with margins positive for lobular carcinoma in situ (LCIS) are eligible. Either mastectomy or breast conserving surgery (including lumpectomy or partial mastectomy) is acceptable.\n* Breast Radiotherapy\n\n  * Radiotherapy is required for participants who underwent breast-conserving therapy, including lumpectomy or partial mastectomy unless deemed inappropriate by the treating provider.\n  * Post mastectomy radiation is at the discretion of the treating physician.\n  * If radiation was given prior to surgery, additional radiation after surgery is not required.\n  * In all cases participants must begin arm assigned therapy no later than 96 days from the last local therapy\n  * Any acute toxicity must have resolved to grade \\< 2 prior to starting arm specific therapy.\n* Must consent to allow submission of blood and archived tumor tissue sample from definitive surgery for next generation sequencing of the tumor. Tumor block is preferred however 14 slides + 1H\\&E can be submitted if necessary. NOTE: Due to possible false positives, ctDNA should not be drawn before completing radiation or less than 14 days from surgery if radiation is not required.\n* Adequate laboratory values must be obtained within 28 days prior to study registration.\n\n  * Hemoglobin (Hgb) \u2265 9.0 g/dL\n  * Platelets \u2265 100 K/mm3\n  * Absolute neutrophil count (ANC) \u2265 1.5 K/mm3\n  * Calculated creatinine clearance of \u2265 50 cc/min using the Cockcroft-Gault formula\n  * Bilirubin \u2264 1.5 ULN (except in participants with documented Gilbert's disease, who must have a total bilirubin \u2264 3.0 mg/dL)\n  * Aspartate aminotransferase (AST, SGOT) \u2264 2.5 ULN\n  * Alanine aminotransferase (ALT, SGPT) \u2264 2.5 ULN\n* Women of childbearing potential and their partners and male subjects and their partners must be willing to use effective contraception (as outlined in protocol) from the time consent is signed until after protocol therapy discontinuation based on package insert or investigator brochure guidelines (See protocol for timeframes).\n* Women of childbearing potential must have a negative urine or serum pregnancy test at screening and within 7 days prior to study registration. Women should be counseled regarding acceptable birth control methods to utilize. If prior to treatment after discussion with the subject it is felt by the treating physician there is a possibility the subject is pregnant a pregnancy test should be repeated. NOTE: Women are considered not of childbearing potential if they are surgically sterile (they have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy), or they are postmenopausal for at least 12 consecutive months.\n* Women must not be breastfeeding from the time of treatment initiation until the number of days after protocol therapy discontinuation based on package insert or investigator brochure guidelines (See protocol for timeframes).\n\nInclusion Criteria for Patients Assigned to Arm 1c ONLY\n\n-Adequate laboratory values must be obtained within 21 days prior to starting arm therapy.\n\n* Fasting total glucose \u2264 126 mg/dL\n* HbA1C \u2264 5.7%\n* Cholesterol \\< 300 mg/dL; 10.34 mmol/L\n* Triglycerides \\< 300 mg/dL; 3.42 mmol/L\n\nGeneral",
        "ExclusionCriteria": "* Clinically significant infections as judged by the treating physician.\n* Stage IV (metastatic) disease, however no specific staging studies are required in the absence of symptoms or physical exam findings that would suggest distant disease.\n* HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of registration are eligible for this trial. NOTE: Patients without a known history of being HIV positive do not require testing at screening. Patients who are known to be HIV positive will require testing as described to be eligible for this trial. Testing should be considered standard of care.\n* Patients with evidence of chronic hepatitis B virus (HBV) infection, with undetectable HBV viral load within 6 months of registration are eligible for this trial. They should be on suppressive therapy, if indicated. Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, the HCV viral load must be undetectable within 6 months of registration to be eligible for this trial. NOTE: Patients without a known history of being hepatitis positive do not require testing at screening. Patients who are known to be hepatitis positive will require testing as described to be eligible for this trial. Testing should be considered standard of care.\n* Participants with unstable angina or a myocardial infarction within 12 months of study registration.\n* Active second malignancy (except non-melanomatous skin cancer or incidental prostate cancer found on cystectomy): Active second malignancy is defined as a current need for cancer therapy or a high possibility (\\> 30%) of recurrence during the study. Previous contralateral breast cancer is allowable unless it meets \"active\" criteria as stated above.\n* Inability to swallow pills.\n* Evidence of significant uncontrolled concomitant disease that could affect compliance with the protocol, safety of participation, or interpretation of results. This includes significant liver disease (such as cirrhosis, uncontrolled major seizure disorder, or superior vena cava syndrome) or any other serious medical condition or abnormality in clinical laboratory tests that meet these criteria in the investigator's opinion.\n* History of severe allergic, anaphylactic, or other hypersensitivity reactions to any of the study medications being used in this study.\n* Treatment with any investigational agent within 30 days prior to study registration.\n\nExclusion Criteria for Patients Assigned to Arm 1c ONLY\n\n* Any concurrent ocular or intraocular condition (e.g., cataract or diabetic retinopathy) that, in the opinion of the investigator, would require medical or surgical intervention during the study period to prevent or treat vision loss that might result from that condition.\n* Type 2 diabetes requiring ongoing systemic treatment at the time of study entry; or any history of Type 1 diabetes.\n* Active inflammatory (e.g., uveitis or vitritis) or infectious (e.g., conjunctivitis, keratitis, scleritis, or endophthalmitis) conditions in either eye or history of idiopathic or autoimmune-associated uveitis in either eye.\n* Symptomatic active lung disease, including pneumonitis\n* History of or active inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis). Patients currently receiving immunosuppressants for inflammatory bowel disease (e.g., sulfasalazine) are considered to have active disease and are therefore ineligible.\n* Any active bowel inflammation (including diverticulitis)\n* Symptomatic hypercalcemia requiring continued use of bisphosphonate or denosumab therapy. Bisphosphonate and denosumab therapy for bone metastases or osteopenia/osteoporosis is allowed.",
        "HealthyVolunteers": false,
        "Gender": "ALL",
        "MinimumAge": "18 Years",
        "NCTId": "NCT04849364",
        "startDate": "",
        "completionDate": "",
        "durationDays": null,
        "daysUntilEnd": null
    },
    {
        "EligibilityCriteria": "Inclusion Criteria:\n\n* Age \\>= 18 years\n* Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2\n* Triple Negative Breast Cancer:\n\n  * Patients with a history of stage T1cN1-2 or T2-4N0-2 breast cancer according to the primary tumor-regional lymph node anatomic staging criteria of the American Joint Committee on Cancer (AJCC), 8th edition as determined by the investigator in radiologic assessment, clinical assessment or both\n  * Patients must have no residual invasive disease in the breast or lymph nodes after the completion of neoadjuvant therapy. Residual ductal carcinoma in situ (DCIS) is allowed. Isolated tumor cells are considered node-negative\n  * Estrogen (ER) and progesterone (PR) =\\< 10%; HER2-negative by American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines (immunohistochemistry \\[IHC\\] and fluorescence in situ hybridization \\[FISH\\])\n  * If invasive disease was present in both breasts, participation in the study is permitted as long as the eligibility criteria are met for both tumors/breasts\n* Patients must have received neoadjuvant chemotherapy in combination with pembrolizumab for a minimum of 6 cycles. All systemic chemotherapy and ICI therapy should have been completed preoperatively\n* An interval of no more than 12 weeks between the completion date of the final surgery and the date of randomization\n\n  \\* Note: Adjuvant radiation can be given on study. If given, it is encouraged to be given concurrently with pembrolizumab, per investigator discretion. Treatment with adjuvant pembrolizumab is strongly discouraged prior to participation in this trial, but if administered (e.g., if patients are awaiting pathology results), pembrolizumab may be administered for up to 6 weeks post-surgery and must be completed prior to registration\n* Use of investigational anti-cancer agents must be discontinued at time of registration\n* Adequate excision: Surgical removal of all clinically evident disease in the breast and lymph nodes as follows:\n\n  * Breast surgery: Total mastectomy or breast-conserving surgery with histologically negative margins, including no ink on tumor for DCIS, at the time of excision\n\n    \\*\\* For patients who undergo breast-conserving surgery, the margins of the resected specimen must be histologically free of ductal carcinoma in-situ (DCIS) as determined by the local pathologist. If pathologic examination demonstrates DCIS at the line of resection, additional operative procedures may be performed to obtain clear margins. If DCIS is still present at the resected margin after re-excision(s), the patient must undergo total mastectomy to be eligible. Patients with margins positive for classic lobular carcinoma in situ (LCIS) are eligible without additional resection\n  * Lymph node surgery:\n\n    * For a patient with clinically N0 disease, a sentinel lymph node biopsy should have been performed at time of surgical evaluation, and if pathologically node positive, the patient is no longer eligible. Isolated tumor cells are considered node-negative\n    * For a patient with clinically N1 disease at diagnosis (with positive results from a fine-needle aspiration, core biopsy, or sentinel node biopsy performed prior to preoperative therapy) additional surgical evaluation of the axilla following preoperative therapy is required\n\n      \\*\\*\\* If they become cN0 (no palpable adenopathy), then a sentinel lymph node biopsy could have been performed at time of surgery (axillary dissection would also be permitted); if the sentinel lymph node biopsy is positive, the patient is no longer eligible\n    * If sentinel node biopsy performed before preoperative therapy was negative, no additional surgical evaluation of the axilla is required after preoperative therapy. If sentinel node biopsy performed before preoperative therapy was positive, an ALND is required after preoperative therapy\n    * If the only sentinel node identified by isotope scan is in the internal mammary chain, surgical evaluation of the axilla is still required\n    * If sentinel node evaluation after preoperative therapy is negative, no further additional surgical evaluation of the axilla is required\n    * Axillary dissection without sentinel node evaluation is permitted as the initial or sole axillary evaluation after preoperative therapy\n* If breast-conserving surgery was performed but patient will not be receiving breast radiation, the patient is not eligible\n* Not pregnant and not nursing, because this study involves an agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown. Therefore, for women of childbearing potential only, a negative serum or urine pregnancy test done =\\< 7 days prior to randomization is required\n* Absolute neutrophil count (ANC) \\>= 1,000/mm\\^3\n* Platelet Count \\>= 100,000/mm\\^3\n* Estimated glomerular filtration rate (eGFR) \\>= 15 mL/min/1.73m\\^2\n* Total Bilirubin =\\<1.5 x upper limit of normal (ULN)\n\n  \\* Patients with Gilbert's disease with a total bilirubin =\\< 2.5 x ULN and direct bilirubin within normal limits are permitted\n* Aspartate aminotransferase (AST) serum aspartate aminotransferase \\[SGOT\\] / alanine aminotransferase (ALT) serum glutamic pyruvic transaminase \\[SGPT\\] =\\< 3 x institutional ULN\n* Patients must be willing to provide tumor tissue from the diagnostic core biopsy. If inadequate tumor tissue is available, patients are still eligible to participate in the trial\n* Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial\n* Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better\n* Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months prior to registration are eligible for this trial\n\nExclusion Criteria:\n\n* No stage IV (metastatic) breast cancer\n* No history of any prior (ipsi- or contralateral) invasive breast cancer. Prior DCIS is allowed\n* No evidence of recurrent disease following preoperative therapy and surgery\n* No known active liver disease, e.g. due to hepatitis B virus (HBV), hepatitis C virus (HCV), autoimmune hepatic disorders, or sclerosing cholangitis\n* No history of intolerance, including Grade 3 or 4 infusion reaction or hypersensitivity to pembrolizumab or murine proteins or any components of the product\n\n  \\* Note: Prior immune-related adverse events (irAEs) are allowed if they resolved and the patient tolerated subsequent therapy without requiring chronic steroids for the irAE\n* No medical conditions that require chronic systemic steroids (\\>10 mg prednisone daily or equivalent) or any other form of immunosuppressive medications and has required such therapy in the last two years. Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic therapy\n* Patients who are unable or unwilling to comply with the requirements of the protocol per investigator assessment are not eligible",
        "InclusionCriteria": "* Age \\>= 18 years\n* Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2\n* Triple Negative Breast Cancer:\n\n  * Patients with a history of stage T1cN1-2 or T2-4N0-2 breast cancer according to the primary tumor-regional lymph node anatomic staging criteria of the American Joint Committee on Cancer (AJCC), 8th edition as determined by the investigator in radiologic assessment, clinical assessment or both\n  * Patients must have no residual invasive disease in the breast or lymph nodes after the completion of neoadjuvant therapy. Residual ductal carcinoma in situ (DCIS) is allowed. Isolated tumor cells are considered node-negative\n  * Estrogen (ER) and progesterone (PR) =\\< 10%; HER2-negative by American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines (immunohistochemistry \\[IHC\\] and fluorescence in situ hybridization \\[FISH\\])\n  * If invasive disease was present in both breasts, participation in the study is permitted as long as the eligibility criteria are met for both tumors/breasts\n* Patients must have received neoadjuvant chemotherapy in combination with pembrolizumab for a minimum of 6 cycles. All systemic chemotherapy and ICI therapy should have been completed preoperatively\n* An interval of no more than 12 weeks between the completion date of the final surgery and the date of randomization\n\n  \\* Note: Adjuvant radiation can be given on study. If given, it is encouraged to be given concurrently with pembrolizumab, per investigator discretion. Treatment with adjuvant pembrolizumab is strongly discouraged prior to participation in this trial, but if administered (e.g., if patients are awaiting pathology results), pembrolizumab may be administered for up to 6 weeks post-surgery and must be completed prior to registration\n* Use of investigational anti-cancer agents must be discontinued at time of registration\n* Adequate excision: Surgical removal of all clinically evident disease in the breast and lymph nodes as follows:\n\n  * Breast surgery: Total mastectomy or breast-conserving surgery with histologically negative margins, including no ink on tumor for DCIS, at the time of excision\n\n    \\*\\* For patients who undergo breast-conserving surgery, the margins of the resected specimen must be histologically free of ductal carcinoma in-situ (DCIS) as determined by the local pathologist. If pathologic examination demonstrates DCIS at the line of resection, additional operative procedures may be performed to obtain clear margins. If DCIS is still present at the resected margin after re-excision(s), the patient must undergo total mastectomy to be eligible. Patients with margins positive for classic lobular carcinoma in situ (LCIS) are eligible without additional resection\n  * Lymph node surgery:\n\n    * For a patient with clinically N0 disease, a sentinel lymph node biopsy should have been performed at time of surgical evaluation, and if pathologically node positive, the patient is no longer eligible. Isolated tumor cells are considered node-negative\n    * For a patient with clinically N1 disease at diagnosis (with positive results from a fine-needle aspiration, core biopsy, or sentinel node biopsy performed prior to preoperative therapy) additional surgical evaluation of the axilla following preoperative therapy is required\n\n      \\*\\*\\* If they become cN0 (no palpable adenopathy), then a sentinel lymph node biopsy could have been performed at time of surgery (axillary dissection would also be permitted); if the sentinel lymph node biopsy is positive, the patient is no longer eligible\n    * If sentinel node biopsy performed before preoperative therapy was negative, no additional surgical evaluation of the axilla is required after preoperative therapy. If sentinel node biopsy performed before preoperative therapy was positive, an ALND is required after preoperative therapy\n    * If the only sentinel node identified by isotope scan is in the internal mammary chain, surgical evaluation of the axilla is still required\n    * If sentinel node evaluation after preoperative therapy is negative, no further additional surgical evaluation of the axilla is required\n    * Axillary dissection without sentinel node evaluation is permitted as the initial or sole axillary evaluation after preoperative therapy\n* If breast-conserving surgery was performed but patient will not be receiving breast radiation, the patient is not eligible\n* Not pregnant and not nursing, because this study involves an agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown. Therefore, for women of childbearing potential only, a negative serum or urine pregnancy test done =\\< 7 days prior to randomization is required\n* Absolute neutrophil count (ANC) \\>= 1,000/mm\\^3\n* Platelet Count \\>= 100,000/mm\\^3\n* Estimated glomerular filtration rate (eGFR) \\>= 15 mL/min/1.73m\\^2\n* Total Bilirubin =\\<1.5 x upper limit of normal (ULN)\n\n  \\* Patients with Gilbert's disease with a total bilirubin =\\< 2.5 x ULN and direct bilirubin within normal limits are permitted\n* Aspartate aminotransferase (AST) serum aspartate aminotransferase \\[SGOT\\] / alanine aminotransferase (ALT) serum glutamic pyruvic transaminase \\[SGPT\\] =\\< 3 x institutional ULN\n* Patients must be willing to provide tumor tissue from the diagnostic core biopsy. If inadequate tumor tissue is available, patients are still eligible to participate in the trial\n* Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial\n* Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better\n* Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months prior to registration are eligible for this trial",
        "ExclusionCriteria": "* No stage IV (metastatic) breast cancer\n* No history of any prior (ipsi- or contralateral) invasive breast cancer. Prior DCIS is allowed\n* No evidence of recurrent disease following preoperative therapy and surgery\n* No known active liver disease, e.g. due to hepatitis B virus (HBV), hepatitis C virus (HCV), autoimmune hepatic disorders, or sclerosing cholangitis\n* No history of intolerance, including Grade 3 or 4 infusion reaction or hypersensitivity to pembrolizumab or murine proteins or any components of the product\n\n  \\* Note: Prior immune-related adverse events (irAEs) are allowed if they resolved and the patient tolerated subsequent therapy without requiring chronic steroids for the irAE\n* No medical conditions that require chronic systemic steroids (\\>10 mg prednisone daily or equivalent) or any other form of immunosuppressive medications and has required such therapy in the last two years. Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic therapy\n* Patients who are unable or unwilling to comply with the requirements of the protocol per investigator assessment are not eligible",
        "HealthyVolunteers": false,
        "Gender": "ALL",
        "MinimumAge": "18 Years",
        "NCTId": "NCT05812807",
        "startDate": "",
        "completionDate": "",
        "durationDays": null,
        "daysUntilEnd": null
    },
    {
        "EligibilityCriteria": "Key Inclusion Criteria:\n\n* All Parts: Age \u2265 18 years, ECOG Performance Status \u2264 1, at least 1 site of measurable disease evaluable by CT scan or MRI per RECIST 1.1, able to take oral medication without alteration\n* Dose Escalation: No available therapeutic options to provide clinically meaningful benefits in the following tumor types: High Grade Serous Ovarian Cancer, Squamous Non -Small Cell Lung Cancer, Triple Negative Breast Cancer, Gastric Adenocarcinoma (not EBV+), Colorectal, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction, Bladder (transitional cell), Head and Neck Squamous Cell Carcinomas (not nasopharynx, sinonasal or lip), Ovarian Carcinosarcoma, CN-high Endometrial/Uterine\n* Dose Expansion: Must have been previously treated with several lines of standard of care treatment specified in the protocol in the following tumor types: High Grade Serous Ovarian Cancer, Squamous Non-Small Cell Lung Cancer, Triple Negative Breast Cancer, Gastric Adenocarcinoma (not EBV+), Colorectal, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Head and Neck Squamous Cell Carcinomas (not nasopharynx, sinonasal or lip), CN-high Endometrial/Uterine\n\nKey Exclusion Criteria:\n\n* MSI-H, dMMR, POLE gene hotspot mutated, or known hypermutator phenotype\n* Previously received KIF18A inhibitor\n* Current CNS metastases or leptomeningeal disease\n* Cardiac parameters: MI or stroke \u2264 1 year, unstable angina/PE/DVT/CABG \u2264 6 months, NYHA Class \u2265 II, LVEF \\< 50%\n* Inability to comply with concomitant medication restrictions with respect to strong inhibitors and inducers of CYP3A, and clinical inhibitors of MDR1 (P-gp) and BCRP\n* Any clinically significant ascites or pleural effusions at time of enrollment, or any therapeutic paracentesis or thoracentesis within 28 days of planned first dose of study drug\n* Bowel obstruction or GI perforation within 6 months of planned first dose of study drug",
        "InclusionCriteria": "* All Parts: Age \u2265 18 years, ECOG Performance Status \u2264 1, at least 1 site of measurable disease evaluable by CT scan or MRI per RECIST 1.1, able to take oral medication without alteration\n* Dose Escalation: No available therapeutic options to provide clinically meaningful benefits in the following tumor types: High Grade Serous Ovarian Cancer, Squamous Non -Small Cell Lung Cancer, Triple Negative Breast Cancer, Gastric Adenocarcinoma (not EBV+), Colorectal, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction, Bladder (transitional cell), Head and Neck Squamous Cell Carcinomas (not nasopharynx, sinonasal or lip), Ovarian Carcinosarcoma, CN-high Endometrial/Uterine\n* Dose Expansion: Must have been previously treated with several lines of standard of care treatment specified in the protocol in the following tumor types: High Grade Serous Ovarian Cancer, Squamous Non-Small Cell Lung Cancer, Triple Negative Breast Cancer, Gastric Adenocarcinoma (not EBV+), Colorectal, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Head and Neck Squamous Cell Carcinomas (not nasopharynx, sinonasal or lip), CN-high Endometrial/Uterine\n\nKey",
        "ExclusionCriteria": "* MSI-H, dMMR, POLE gene hotspot mutated, or known hypermutator phenotype\n* Previously received KIF18A inhibitor\n* Current CNS metastases or leptomeningeal disease\n* Cardiac parameters: MI or stroke \u2264 1 year, unstable angina/PE/DVT/CABG \u2264 6 months, NYHA Class \u2265 II, LVEF \\< 50%\n* Inability to comply with concomitant medication restrictions with respect to strong inhibitors and inducers of CYP3A, and clinical inhibitors of MDR1 (P-gp) and BCRP\n* Any clinically significant ascites or pleural effusions at time of enrollment, or any therapeutic paracentesis or thoracentesis within 28 days of planned first dose of study drug\n* Bowel obstruction or GI perforation within 6 months of planned first dose of study drug",
        "HealthyVolunteers": false,
        "Gender": "ALL",
        "MinimumAge": "18 Years",
        "NCTId": "NCT05902988",
        "startDate": "",
        "completionDate": "",
        "durationDays": null,
        "daysUntilEnd": null
    },
    {
        "EligibilityCriteria": "Key Inclusion Criteria:\n\n* Age \\> 18 years, with residual invasive triple negative breast cancer (TNBC) in the breast or lymph nodes after neoadjuvant therapy and surgery:\n\n  * TNBC criteria for the study is defined as estrogen receptor (ER) and progesterone receptor (PR) \\< 10%, human epidermal growth factor receptor 2 (HER2)-negative per American Society of Clinical Oncology and College of American Pathologists (ASCO/CAP) guidelines (immunohistochemistry (IHC) and/or in situ hybridization (ISH)).\n* Adequate excision and surgical removal of all clinically evident of disease in the breast and/or lymph nodes and have adequately recovered from surgery.\n* Submission of both pre-neoadjuvant treatment diagnostic biopsy and resected residual invasive disease tissue.\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-1.\n* Individuals must have received appropriate radiotherapy and have recovered prior to starting study treatment.\n* Adequate organ function.\n\nKey Exclusion Criteria:\n\n* Stage IV (metastatic) breast cancer as well as history of any prior (ipsi- or contralateral) invasive breast cancer.\n* Prior treatment with another stimulatory or coinhibitory T-cell receptor agent (eg, cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), OX-40, cluster of differentiation 137 (CD137), prior treatment with any HER2-directed agent, prior or concurrent treatment with any endocrine therapy agent.\n* Evidence of recurrent disease following preoperative therapy and surgery.\n* Prior treatment with topoisomerase 1 inhibitors or antibody-drug conjugates (ADCs) containing a topoisomerase inhibitor.\n* Individuals with germline breast cancer gene (BRCA) mutations.\n* Myocardial infarction or unstable angina pectoris within 6 months of enrollment or history of serious ventricular arrhythmia (ie, ventricular tachycardia or ventricular fibrillation), high-grade atrioventricular block, or other cardiac arrhythmias or Left ventricular ejection fraction (LVEF) of \\< 50%\n* Active serious infections requiring anti-microbial therapy.\n\nNote: Other protocol defined Inclusion/Exclusion criteria may apply.",
        "InclusionCriteria": "* Age \\> 18 years, with residual invasive triple negative breast cancer (TNBC) in the breast or lymph nodes after neoadjuvant therapy and surgery:\n\n  * TNBC criteria for the study is defined as estrogen receptor (ER) and progesterone receptor (PR) \\< 10%, human epidermal growth factor receptor 2 (HER2)-negative per American Society of Clinical Oncology and College of American Pathologists (ASCO/CAP) guidelines (immunohistochemistry (IHC) and/or in situ hybridization (ISH)).\n* Adequate excision and surgical removal of all clinically evident of disease in the breast and/or lymph nodes and have adequately recovered from surgery.\n* Submission of both pre-neoadjuvant treatment diagnostic biopsy and resected residual invasive disease tissue.\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-1.\n* Individuals must have received appropriate radiotherapy and have recovered prior to starting study treatment.\n* Adequate organ function.\n\nKey",
        "ExclusionCriteria": "* Stage IV (metastatic) breast cancer as well as history of any prior (ipsi- or contralateral) invasive breast cancer.\n* Prior treatment with another stimulatory or coinhibitory T-cell receptor agent (eg, cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), OX-40, cluster of differentiation 137 (CD137), prior treatment with any HER2-directed agent, prior or concurrent treatment with any endocrine therapy agent.\n* Evidence of recurrent disease following preoperative therapy and surgery.\n* Prior treatment with topoisomerase 1 inhibitors or antibody-drug conjugates (ADCs) containing a topoisomerase inhibitor.\n* Individuals with germline breast cancer gene (BRCA) mutations.\n* Myocardial infarction or unstable angina pectoris within 6 months of enrollment or history of serious ventricular arrhythmia (ie, ventricular tachycardia or ventricular fibrillation), high-grade atrioventricular block, or other cardiac arrhythmias or Left ventricular ejection fraction (LVEF) of \\< 50%\n* Active serious infections requiring anti-microbial therapy.\n\nNote: Other protocol defined Inclusion/Exclusion criteria may apply.",
        "HealthyVolunteers": false,
        "Gender": "ALL",
        "MinimumAge": "18 Years",
        "NCTId": "NCT05633654",
        "startDate": "",
        "completionDate": "",
        "durationDays": null,
        "daysUntilEnd": null
    }
]